Addex Therapeutics (CH:ADXN)
:ADXN
Want to see CH:ADXN full AI Analyst Report?
Top Page
Addex Therapeutics
(ADXN)
Select Model
Select Model
Rating:46Neutral
Price Target:
CHF0.04
Action:N/A
Date:05/08/26
The score is driven primarily by weak financial performance—especially persistent cash burn and inconsistent/negative profitability—partially offset by low balance-sheet leverage. Technicals are mildly bearish with the price below key long-term averages, and valuation support is limited due to negative earnings and no dividend.
Positive Factors
Low leverage
Very low leverage reduces insolvency and interest-rate risk, preserving financial optionality for R&D. With minimal debt the company can prioritize equity or partnership financing, maintaining flexibility to fund clinical programs and survive development cycles over the next months.
Negative Factors
Persistent cash burn
Consistent negative operating and free cash flow signals ongoing cash burn and financing dependency. Even with 2025 improvement, continuous outflows raise dilution risk, limit capacity to run parallel trials and increase execution risk if partner funding or new financing is delayed.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage
Very low leverage reduces insolvency and interest-rate risk, preserving financial optionality for R&D. With minimal debt the company can prioritize equity or partnership financing, maintaining flexibility to fund clinical programs and survive development cycles over the next months.
Read all positive factors
Addex Therapeutics (ADXN) vs. iShares MSCI Switzerland ETF (EWL)
Market Cap
CHF5.24M
Dividend YieldN/A
Average Volume (3M)206.07K
Price to Earnings (P/E)―
Beta (1Y)0.28
Revenue Growth-57.84%
EPS Growth-187.97%
CountryCH
Employees2
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.07
Shares Outstanding218,654,500
10 Day Avg. Volume188,431
30 Day Avg. Volume206,072
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.30
Price to Sales (P/S)35.91
P/FCF Ratio-2.86
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Addex Therapeutics Business Overview & Revenue Model
Company Description
Addex Therapeutics Ltd, a biopharmaceutical company in its development phase, specializes in the discovery, progression, and commercialization of small-molecule pharmaceutical products designed to address central nervous system (CNS) conditions. B...
How the Company Makes Money
Addex Therapeutics primarily makes money through (1) collaboration and partnering arrangements and (2) external financing, rather than product sales, because it is a clinical-stage company without commercialized products. Under collaboration/licen...
Addex Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
28
Negative
| Breakdown | Dec 2025 | Mar 2025 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 173.00K | 410.04K | 1.61M | 1.42M | 2.92M |
| Gross Profit | 164.39K | -444.26K | -5.32M | -13.20M | -9.67M |
| EBITDA | -2.81M | -4.65M | -10.26M | -20.43M | -14.94M |
| Net Income | -6.73M | 7.06M | -10.56M | -20.80M | -15.41M |
Balance Sheet | |||||
| Total Assets | 6.36M | 10.67M | 4.64M | 8.28M | 22.54M |
| Cash, Cash Equivalents and Short-Term Investments | 1.64M | 3.34M | 3.87M | 6.96M | 20.50M |
| Total Debt | 34.69K | 41.99K | 344.34K | 373.13K | 482.01K |
| Total Liabilities | 1.60M | 1.00M | 3.50M | 3.37M | 5.61M |
| Stockholders Equity | 4.76M | 9.67M | 1.15M | 4.91M | 16.93M |
Cash Flow | |||||
| Free Cash Flow | -2.17M | -5.37M | -8.00M | -16.44M | -14.74M |
| Operating Cash Flow | -2.17M | -5.37M | -7.99M | -16.44M | -14.71M |
| Investing Cash Flow | -680.69K | 4.65M | -6.84K | 2.97K | -30.31K |
| Financing Cash Flow | 1.19M | 104.97K | 5.26M | 3.10M | 16.40M |
Addex Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
Addex Therapeutics Corporate Events
Addex Sets 2026 AGM With Capital and Governance Changes on Agenda
Jun 5, 2026
Addex Therapeutics has scheduled its 2026 Annual General Meeting for June 29 in Geneva, where shareholders will vote on routine corporate matters including approval of the 2025 financial statements, discharge of the board and executive management,...
Addex Advances Neurology Pipeline but Swings to 2025 Net Loss
Apr 30, 2026
Addex Therapeutics reported steady progress across its pipeline in 2025, advancing a GABAB PAM candidate for chronic cough through preclinical development and preparing dipraglurant for clinical studies in post-stroke and traumatic brain injury re...
Addex Posts Promising Preclinical Data for GABAB Modulator in IPF-Related Chronic Cough
Apr 29, 2026
Addex Therapeutics reported encouraging preclinical results for its GABAB positive allosteric modulator in a bleomycin-induced idiopathic pulmonary fibrosis chronic cough model, showing robust and sustained reductions in cough frequency and longer...
Addex Spin-Out Neurosterix Nears Completion of Phase 1 Schizophrenia Trial for NTX-253
Apr 23, 2026
Spin-out Neurosterix, in which Addex Therapeutics holds a 20% stake, is on track to complete a Phase 1 trial of NTX-253, an oral muscarinic M4 positive allosteric modulator for schizophrenia, in the second quarter of 2026. The study is designed to...
Addex Reports Robust Preclinical Efficacy for Novel GABAB Modulator in Chronic Cough
Apr 21, 2026
Addex Therapeutics reported robust anti-tussive activity for its novel GABAB positive allosteric modulator in a non-human primate chronic cough model, where the candidate significantly reduced citric acid-induced cough frequency with efficacy comp...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.